Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

MEK

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer

Xue S, Xu H, Ma J, et al.

Cancer letters

This study investigates resistance mechanisms to KRAS G12D inhibitors, such as HRS-4642, in pancreatic ductal adenocarcinoma (PDAC). Researchers identified the reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key mechanism of acquired resistance, observed in vitro, in vivo, and in patients. To overcome this resistance, a combination therapy with nimotuzumab was tested, demonstrating strong synergy and resistance reversal. Nimotuzumab sustained the suppression of the MEK/ERK/UPR axis while exacerbating endoplasmic reticulum stress, leading to profound cellular damage. These findings suggest a promising combined strategy for PDAC patients harboring KRAS G12D mutations.